Insider Selling: Disc Medicine, Inc. (NASDAQ:IRON) Director Sells $81,408.00 in Stock

Disc Medicine, Inc. (NASDAQ:IRON) Director William Richard White sold 2,560 shares of the firm’s stock in a transaction that occurred on Thursday, April 11th. The stock was sold at an average price of $31.80, for a total transaction of $81,408.00. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Disc Medicine Trading Up 1.2 %

Shares of NASDAQ:IRON opened at $30.28 on Thursday. The stock’s fifty day simple moving average is $56.51 and its two-hundred day simple moving average is $55.57. Disc Medicine, Inc. has a 1-year low of $23.30 and a 1-year high of $77.60. The stock has a market cap of $730.96 million, a PE ratio of -8.68 and a beta of 0.18.

Disc Medicine (NASDAQ:IRON) last issued its quarterly earnings data on Thursday, March 21st. The company reported ($0.97) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.22). On average, sell-side analysts forecast that Disc Medicine, Inc. will post -4.44 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on IRON. Raymond James reaffirmed an “outperform” rating and set a $40.00 price objective (down previously from $75.00) on shares of Disc Medicine in a research report on Monday, April 1st. Cantor Fitzgerald reiterated an “overweight” rating and issued a $85.00 target price on shares of Disc Medicine in a report on Wednesday, December 20th. Morgan Stanley cut their target price on Disc Medicine from $75.00 to $40.00 and set an “equal weight” rating on the stock in a report on Tuesday, April 2nd. HC Wainwright reiterated a “buy” rating and issued a $70.00 target price on shares of Disc Medicine in a report on Monday, April 1st. Finally, BMO Capital Markets cut their target price on Disc Medicine from $80.00 to $50.00 and set an “outperform” rating on the stock in a report on Tuesday, April 2nd. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $57.29.

Hedge Funds Weigh In On Disc Medicine

Several large investors have recently bought and sold shares of IRON. Citadel Advisors LLC increased its position in shares of Disc Medicine by 280.4% during the 2nd quarter. Citadel Advisors LLC now owns 651,320 shares of the company’s stock valued at $28,919,000 after purchasing an additional 480,082 shares during the last quarter. BlackRock Inc. raised its stake in shares of Disc Medicine by 2,041.5% during the 2nd quarter. BlackRock Inc. now owns 502,549 shares of the company’s stock worth $22,313,000 after purchasing an additional 479,082 shares during the period. Sphera Funds Management LTD. bought a new stake in shares of Disc Medicine during the 1st quarter worth $4,662,000. First Turn Management LLC bought a new stake in shares of Disc Medicine during the 4th quarter worth $9,084,000. Finally, Adage Capital Partners GP L.L.C. raised its stake in shares of Disc Medicine by 12.5% during the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 1,308,405 shares of the company’s stock worth $61,469,000 after purchasing an additional 145,781 shares during the period. 83.70% of the stock is currently owned by institutional investors.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.